MiMedx Group, Inc

Sep 23, 2026

MDXGFDA Updates

MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter

MiMedx Group, Inc. announced a favorable ruling from the U.S. District Court regarding the regulatory classification of AXIOFILL. The Court vacated the FDA's previous determinations, stating that the agency's interpretation of minimal manipulation was incorrect. The ruling requires the FDA to reconsider AXIOFILL's classification, which could impact its market positioning.

Sep 8, 2026

MIMEDX to Participate in Upcoming Investor Conferences

MiMedx Group, Inc. announced its participation in two upcoming investor conferences in New York. The Cantor Global Healthcare Conference will take place on September 9, 2026, followed by the Lake Street BIG10 Best Ideas Growth Conference on September 10, 2026. Investors interested in meetings can contact their respective conference representatives.

Jul 29, 2026

MIMEDX Announces Second Quarter 2026 Operating & Financial Results

MiMedx Group, Inc. reported second quarter 2026 net sales of $64 million, a 35% decrease from the previous year. The company highlighted a 15% growth in its Surgical franchise and a 22% increase in Wound volume, signaling recovery. MiMedx also announced plans to acquire Sanara MedTech, aiming to strengthen its market position. Despite challenges, management remains optimistic about achieving profitability in the latter half of the year.

Jul 20, 2026

MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29

MiMedx Group, Inc. will announce its second quarter 2026 operating and financial results on July 29, 2026. The results will be shared during a conference call at 4:30 p.m. ET, accessible to both U.S. and international investors. A replay of the call will be available for 30 days on their website.

May 21, 2026

MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference

MiMedx Group, Inc. announced its participation in the Craig-Hallum 23rd Annual Institutional Investor Conference scheduled for May 28, 2026, in Minneapolis, MN. Senior management will be available for meetings with interested investors. The company is recognized for its innovative solutions in wound care and healing.

May 8, 2026

MIMEDX Announces Launch of G4Derm® Plus

MiMedx Group, Inc. has launched G4Derm Plus, a flowable biomimetic matrix designed for advanced wound management. The product, which utilizes self-assembling peptide technology, is now available through major group purchasing organizations like Premier and Vizient. Initial sales have been reported, indicating strong demand. Experts believe it will enhance treatment options for complex wounds.

MIMEDX Announces First Quarter 2026 Operating & Financial Results

MiMedx Group, Inc. reported its first quarter 2026 results, revealing net sales of $59 million, a significant drop from $88 million in the same quarter last year. The decline is primarily attributed to the impact of new Medicare reimbursement policies on their wound care products, which faced a 60% decrease in sales. Despite challenges, the surgical division showed a 13% increase in sales, and management is optimistic about recovering sales volumes in wound care settings. They have also revised their financial expectations for the full year downward and anticipate cost benefits from restructuring efforts.

Apr 22, 2026

MIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29

MiMedx Group, Inc. will announce its first quarter 2026 operating and financial results on April 29, 2026. The results will be shared in a conference call starting at 4:30 p.m. Eastern Time. Investors can access the call via a dedicated phone line or webcast, with a replay available for 30 days afterward.

MIMEDX Announces Restructuring and Cost Reduction Initiative

MiMedx Group, Inc. announced a restructuring initiative to reduce operating expenses by approximately $40 million. The elimination of the COO position is part of this effort, as the company aims to streamline operations and prioritize growth. The Wound Care business is recovering slowly from recent Medicare reimbursement reductions, prompting these changes.

Apr 16, 2026

▼ -11.6%on this newsshared move

forth in the forward-looking statements. Any forward-looking statements speak only as of the date of this press release and the Company assumes no obligation to update any forward-looking statement. About MIMEDX MIMEDX i

MIMEDX has announced a major restructuring aimed at improving profitability by reducing annual operating expenses by approximately $40 million. This organizational change comes as the company faces slow recovery in its Wound Care business following a reduction in Medicare reimbursements. The position of Chief Operating Officer has been eliminated as part of these changes, indicating a significant shift in the company's operational structure. Leadership change and adjustments are expected to be discussed in an upcoming quarterly conference call.

Apr 2, 2026

MIMEDX to Sponsor Leading Advanced Wound Care Conferences

MiMedx Group, Inc. will participate in two prominent wound care conferences, SAWC Spring 2026 and DLS 2026. The company plans to present its advanced wound care technologies and clinical evidence through various sessions. MIMEDX aims to support clinicians in managing complex wounds and improve patient outcomes with innovative solutions.

Mar 23, 2026

MIMEDX Announces Launch of CHORIOFIX™

MiMedx Group, Inc. has launched CHORIOFIX, an advanced wound care product featuring two chorion layers and an intact intermediate layer. This product is designed to enhance handling during application and is particularly suited for complex wound types. CHORIOFIX will also be evaluated in the CAMPAIGN trial against standard care for diabetic foot ulcers.

Mar 5, 2026

MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX® Thyroid Shields

MiMedx Group, Inc. has launched AMNIOFIX Thyroid Shields, a new product designed for use in endocrine surgery. These allografts provide a protective barrier for the recurrent laryngeal nerve and parathyroid glands post-thyroidectomy, significantly reducing the risk of nerve damage. The product is shelf-stable for five years and aims to improve surgical outcomes.

MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results

MiMedx Group, Inc. reported record financial results for Q4 and full year 2025, with net sales increasing by 27% year-over-year. The company achieved a GAAP net income of $15 million and an Adjusted EBITDA margin of 25%. Looking ahead, MiMedx anticipates 2026 net sales between $340-360 million, despite potential short-term impacts from Medicare reimbursement changes.

Feb 17, 2026

MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25

MiMedx Group, Inc. will announce its operating and financial results for Q4 and the full year 2025 on February 25, 2026. The results will be shared during a conference call hosted by the senior management team at 4:30 p.m. ET. Investors can access the call via a dedicated phone line or webcast.

Feb 4, 2026

MIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products

MiMedx Group, Inc. has entered an exclusive distribution agreement with Summit Products Group to distribute three innovative surgical and wound care products: Hydrelix, NovaForm, and G4Derm Plus. This partnership aims to enhance MiMedx's existing product portfolio and strengthen its position in the Surgical & Wound markets. The agreement reflects MiMedx's commitment to innovation and quality in healthcare solutions.

Feb 2, 2026

MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®

MiMedx Group, Inc. celebrates the 15th anniversary of its placental allografts, EPIFIX and AMNIOFIX. These products have significantly impacted wound care and surgical recovery, being recognized for their extensive clinical studies and peer-reviewed data. The company highlights its commitment to innovation and improving patient outcomes in various surgical fields.

Dec 22, 2025

MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit -Wound Gel

MiMedx Group, Inc. has announced an exclusive distribution agreement with Regen Lab USA LLC for their RegenKit-Wound Gel in the U.S. This product is an autologous platelet-rich plasma and thrombin serum gel designed for chronic wound treatment, supported by various studies. The agreement adds an innovative option to MIMEDX's Advanced Wound Care portfolio. Additionally, a recent regulatory clarity on Local Coverage Determination will bolster the company's market position starting in January 2026.

Dec 19, 2025

MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro

MiMedx Group, Inc. announced a new publication in the Journal of Inflammation detailing the immunomodulatory effects of its Purion processed human amniotic membrane allografts. The study found that both DHACM and LHACM products effectively regulate inflammatory responses, which could enhance wound healing. This research adds to MiMedx's extensive body of evidence supporting its innovative products.